Diffuse Large B-Cell Lymphoma Presenting Primarily as a Cutaneous Leg Lesion: A Case Report and Literature Review.

Primary cutaneous B-cell lymphoma (PCBCL) has three subtypes, among those, the leg type variant is the rarest with the highest rates of relapse and recurrence making it an intriguing focus for researchers. Nevertheless, prior to framing a diagnosis solely based on the lesion's location, it is prudent to reconsider whether it is genuinely a primary cutaneous B-cell lymphoma (PCBCL) or if it aligns more closely with the more prevalent lymphoma variants such as diffuse large B-cell lymphoma (DLBCL) with cutaneous involvement. We are reporting a case of an 85-year-old African American lady, who presented with unilateral left leg DLBCL with cutaneous involvement.

Characterization of PFAS residuals: A case study on PFAS content in a firefighting foam delivery system of an aircraft rescue and firefighting vehicle.

When fire suppression systems that held aqueous film forming foams (AFFF) are transitioned to per- and polyfluoroalkyl substance (PFAS)-free firefighting formulations, PFAS can dissolve from the wetted surfaces of the systems and release into the new firefighting formulations. The overall objective of this work was to characterize PFAS residual mass on the wetted surfaces of aircraft rescue and firefighting (ARFF) vehicle on-board fire suppression system components from the water, mixed fire water, and foam concentrate systems with various geometries, materials of construction, and locations within the fire suppression system. The ARFF vehicle components were dismantled from the system after a triple water rinse procedure which removed 19,600 mg total measured PFAS post-TOP assay from the foam concentrate system and 23 mg total measured PFAS post-TOP assay from the water system.

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study.

Background: Crizanlizumab is a novel inhibitor of P-selectin, a key player in multicellular adhesion and inflammatory signaling, that leads to vaso-occlusion in sickle cell disease (SCD).

Objectives: The SOLACE-adults study evaluated the pharmacokinetics, pharmacodynamics (P-selectin inhibition), safety, and efficacy of crizanlizumab, with or without hydroxyurea/hydroxycarbamide, in patients with SCD.

Design: Phase II, single-arm, multicenter study.

The use of abstract animations and a graphical body image for assessing pain outcomes among adults with sickle cell disease.

Painimation, a novel digital pain assessment tool, allows patients to communicate their pain quality, intensity, and location using abstract animations (painimations) and a paintable body image. This study determined the construct validity of painimations and body image measures by testing correlations with validated pain outcomes in adults with sickle cell disease (SCD). Analyses used baseline data from a multisite randomized trial of 359 adults with SCD and chronic pain.